Predictive biomarkers in renal cell cancer: Insights in drug resistance mechanisms

Drug Resistance Updates

Volumn 17, Issue 4-6, 2014, Pages 77-88

  Van Der Mijn, Johannes C ^a,b   Mier, James W ^b   Broxterman, Henk J ^a   Verheul, Henk M ^a  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Predictive biomarker; Renal cell carcinoma; VEGF targeted therapy

Indexed keywords

ANGIOGENESIS INHIBITOR; TUMOR MARKER; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

CARCINOMA, RENAL CELL; DISEASE FREE SURVIVAL; DRUG RESISTANCE; HUMAN; KIDNEY NEOPLASMS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; TREATMENT OUTCOME; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; CARCINOMA, RENAL CELL; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; HUMANS; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84914115390     PISSN: 13687646     EISSN: 15322084     Source Type: Journal    
DOI: 10.1016/j.drup.2014.10.003     Document Type: Review

References (92)

1. Y. Adar, M. Stark, E.E. Bram, P. Nowak-Sliwinska, H. van den Bergh, and G. Szewczyk Imidazoacridinone-dependent lysosomal photodestruction: a pharmacological trojan horse approach to eradicate multidrug-resistant cancers Cell Death Dis. 3 April 2012 e293
2. M.Y. Al-Marrawi, B.I. Rini, L.C. Harshman, G. Bjarnason, L. Wood, and U. Vaishampayan The association of clinical outcome to first-line VEGF-targeted therapy with clinical outcome to second-line VEGF-targeted therapy in metastatic renal cell carcinoma patients Target Oncol. 8 September (3) 2013 203 209
3. J. Barbastefano, J.A. Garcia, P. Elson, L.S. Wood, B.R. Lane, and R. Dreicer Association of percentage of tumour burden removed with debulking nephrectomy and progression-free survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy BJU Int. 106 November (9) 2010 1266 1269
4. G. Bergers, and D. Hanahan Modes of resistance to anti-angiogenic therapy Nat. Rev. Cancer 8 August (8) 2008 592 603
5. B. Beuselinck, A. Karadimou, D. Lambrechts, B. Claes, P. Wolter, and G. Couchy Single-nucleotide polymorphisms associated with outcome in metastatic renal cell carcinoma treated with sunitinib Br. J. Cancer 108 March (4) 2013 887 900
6. B. Beuselinck, A. Karadimou, D. Lambrechts, B. Claes, P. Wolter, and G. Couchy VEGFR1 single nucleotide polymorphisms associated with outcome in patients with metastatic renal cell carcinoma treated with sunitinib - a multicentric retrospective analysis Acta Oncol. 53 January (1) 2014 103 112
7. J. Busch, C. Seidel, S. Weikert, I. Wolff, C. Kempkensteffen, and L. Weinkauf Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma BMC Cancer 11 July 2011 295 2407-11-295
8. Cancer Genome Atlas Research Network Comprehensive molecular characterization of clear cell renal cell carcinoma Nature 499 July (7456) 2013 43 49
9. O. Casanovas, D.J. Hicklin, G. Bergers, and D. Hanahan Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 8 October (4) 2005 299 309
10. D. Cella, J.C. Cappelleri, A. Bushmakin, C. Charbonneau, J.Z. Li, and S.T. Kim Quality of life predicts progression-free survival in patients with metastatic renal cell carcinoma treated with sunitinib versus interferon alfa J. Oncol. Pract. 5 March (2) 2009 66 70
11. T.K. Choueiri, J.A. Garcia, P. Elson, M. Khasawneh, S. Usman, and A.R. Golshayan Clinical factors associated with outcome in patients with metastatic clear-cell renal cell carcinoma treated with vascular endothelial growth factor-targeted therapy Cancer 110 August (3) 2007 543 550
12. T.K. Choueiri, S. Cheng, A.Q. Qu, J. Pastorek, M.B. Atkins, and S. Signoretti Carbonic anhydrase IX as a potential biomarker of efficacy in metastatic clear-cell renal cell carcinoma patients receiving sorafenib or placebo: analysis from the treatment approaches in renal cancer global evaluation trial (TARGET) Urol. Oncol. 31 November (8) 2012 1788 1793 10.1016/j.urolonc.2012.07.004
13. T.K. Choueiri, A.P. Fay, R. Gagnon, Y. Lin, B. Bahamon, and V. Brown The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma Clin. Cancer Res. 19 September (18) 2013 5218 5226
14. S.E. Deprimo, C.L. Bello, J. Smeraglia, C.M. Baum, D. Spinella, and B.I. Rini Circulating protein biomarkers of pharmacodynamic activity of sunitinib in patients with metastatic renal cell carcinoma: modulation of VEGF and VEGF-related proteins J. Transl. Med. 5 July 2007 32
15. M.H. Diekstra, H.J. Klumpen, M.P. Lolkema, H. Yu, J.S. Kloth, and H. Gelderblom Association analysis of genetic polymorphisms in genes related to sunitinib pharmacokinetics, specifically clearance of sunitinib and SU12662 Clin. Pharmacol. Ther. 96 July (1) 2014 81 89 10.1038/clpt.2014.47
16. J. Dornbusch, A. Zacharis, M. Meinhardt, K. Erdmann, I. Wolff, and M. Froehner Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma PLOS ONE 8 September (9) 2013 e76386
17. K. Eechoute, A.A. van der Veldt, S. Oosting, M.H. Kappers, J.A. Wessels, and H. Gelderblom Polymorphisms in endothelial nitric oxide synthase (eNOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension Clin. Pharmacol. Ther. 92 October (4) 2012 503 510
18. B. Escudier, T. Eisen, W.M. Stadler, C. Szczylik, S. Oudard, and M. Staehler Sorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J. Clin. Oncol. 27 July (20) 2009 3312 3318
19. D.R. Feldman, M.S. Baum, M.S. Ginsberg, H. Hassoun, C.D. Flombaum, and S. Velasco Phase I trial of bevacizumab plus escalated doses of sunitinib in patients with metastatic renal cell carcinoma J. Clin. Oncol. 27 Mar (9) 2009 1432 1439
20. K.T. Flaherty, M.A. Rosen, D.F. Heitjan, M.L. Gallagher, B. Schwartz, and M.D. Schnall Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma Cancer Biol. Ther. 7 April (4) 2008 496 501
21. L.S. Fournier, S. Oudard, R. Thiam, L. Trinquart, E. Banu, and J. Medioni Metastatic renal carcinoma: evaluation of antiangiogenic therapy with dynamic contrast-enhanced CT Radiology 256 August (2) 2010 511 518
22. T. Fujita, M. Iwamura, D. Ishii, K. Tabata, K. Matsumoto, and K. Yoshida C-reactive protein as a prognostic marker for advanced renal cell carcinoma treated with sunitinib Int. J. Urol. 19 October (10) 2012 908 913
23. J. Garcia-Donas, E. Esteban, L.J. Leandro-Garcia, D.E. Castellano, A.G. del Alba, and M.A. Climent Single nucleotide polymorphism associations with response and toxic effects in patients with advanced renal-cell carcinoma treated with first-line sunitinib: a multicentre, observational, prospective study Lancet Oncol. 12 November (12) 2011 1143 1150
24. J. Garcia-Donas, L.J. Leandro-Garcia, A. Gonzalez Del Alba, M. Morente, I. Alemany, and E. Esteban Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma Ann. Oncol. 24 September (9) 2013 2409 2414
25. K.J. Gotink, and H.M. Verheul Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 13 March (1) 2010 1 14
26. K.J. Gotink, H.J. Broxterman, M. Labots, R.R. de Haas, H. Dekker, and R.J. Honeywell Lysosomal sequestration of sunitinib: a novel mechanism of drug resistance Clin. Cancer Res. 17 December (23) 2011 7337 7346
27. A.W. Griffioen, L.A. Mans, A.M. de Graaf, P. Nowak-Sliwinska, C.L. de Hoog, and T.A. de Jong Rapid angiogenesis onset after discontinuation of sunitinib treatment of renal cell carcinoma patients Clin. Cancer Res. 18 July (14) 2012 3961 3971
28. V. Gruenwald, G. Beutel, S. Schuch-Jantsch, C. Reuter, P. Ivanyi, and A. Ganser Circulating endothelial cells are an early predictor in renal cell carcinoma for tumor response to sunitinib BMC Cancer 10 December 2010 695 2407-10-695
29. O.M. Hahn, C. Yang, M. Medved, G. Karczmar, E. Kistner, and T. Karrison Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma J. Clin. Oncol. 26 October (28) 2008 4572 4578
30. K.S. Han, D.C. Jung, H.J. Choi, M.S. Jeong, K.S. Cho, and J.Y. Joung Pretreatment assessment of tumor enhancement on contrast-enhanced computed tomography as a potential predictor of treatment outcome in metastatic renal cell carcinoma patients receiving antiangiogenic therapy Cancer 116 May (10) 2010 2332 2342
31. D.Y. Heng, M.J. Mackenzie, U.N. Vaishampayan, G.A. Bjarnason, J.J. Knox, and M.H. Tan Primary anti-vascular endothelial growth factor (VEGF)-refractory metastatic renal cell carcinoma: clinical characteristics, risk factors, and subsequent therapy Ann. Oncol. 23 June (6) 2012 1549 1555
32. D.Y. Heng, W. Xie, M.M. Regan, L.C. Harshman, G.A. Bjarnason, and U.N. Vaishampayan External validation and comparison with other models of the international metastatic renal-cell carcinoma database consortium prognostic model: a population-based study Lancet Oncol. 14 February (2) 2013 141 148
33. E. Herrmann, J. Gerss, S. Bierer, T. Kopke, C. Bolenz, and L. Hertle Pre-treatment global quality of health predicts progression free survival in metastatic kidney cancer patients treated with sorafenib or sunitinib J. Cancer Res. Clin. Oncol. 135 January (1) 2009 61 67
34. B.E. Houk, C.L. Bello, B. Poland, L.S. Rosen, G.D. Demetri, and R.J. Motzer Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis Cancer Chemother. Pharmacol. 66 July (2) 2010 357 371
35. E. Jonasch, P. Corn, L.C. Pagliaro, C.L. Warneke, M.M. Johnson, and P. Tamboli Upfront, randomized, phase 2 trial of sorafenib versus sorafenib and low-dose interferon alfa in patients with advanced renal cell carcinoma: clinical and biomarker analysis Cancer 116 January (1) 2010 57 65
36. I. Kayani, N. Avril, J. Bomanji, S. Chowdhury, A. Rockall, and A. Sahdev Sequential FDG-PET/CT as a biomarker of response to sunitinib in metastatic clear cell renal cancer Clin. Cancer Res. 17 September (18) 2011 6021 6028
37. J.J. Kim, S.A. Vaziri, B.I. Rini, P. Elson, J.A. Garcia, and R. Wirka Association of VEGF and VEGFR2 single nucleotide polymorphisms with hypertension and clinical outcome in metastatic clear cell renal cell carcinoma patients treated with sunitinib Cancer 118 April (7) 2012 1946 1954
38. J.S. Ko, A.H. Zea, B.I. Rini, J.L. Ireland, P. Elson, and P. Cohen Sunitinib mediates reversal of myeloid-derived suppressor cell accumulation in renal cell carcinoma patients Clin. Cancer Res. 15 March (6) 2009 2148 2157
39. J.S. Ko, P. Rayman, J. Ireland, S. Swaidani, G. Li, and K.D. Bunting Direct and differential suppression of myeloid-derived suppressor cell subsets by sunitinib is compartmentally constrained Cancer Res. 70 May (9) 2010 3526 3536
40. L.F. Kontovinis, K.T. Papazisis, P. Touplikioti, C. Andreadis, D. Mouratidou, and A.H. Kortsaris Sunitinib treatment for patients with clear-cell metastatic renal cell carcinoma: clinical outcomes and plasma angiogenesis markers BMC Cancer 9 March 2009 82 2407-9-82
41. K.M. Krajewski, M. Guo, A.D. Van den Abbeele, J. Yap, N. Ramaiya, and J. Jagannathan Comparison of four early posttherapy imaging changes (EPTIC; RECIST 1.0, tumor shrinkage, computed tomography tumor density, choi criteria) in assessing outcome to vascular endothelial growth factor-targeted therapy in patients with advanced renal cell carcinoma Eur. Urol. 59 May (5) 2011 856 862
42. D. Lambrechts, B. Claes, P. Delmar, J. Reumers, M. Mazzone, and B.T. Yesilyurt VEGF pathway genetic variants as biomarkers of treatment outcome with bevacizumab: an analysis of data from the AViTA and AVOREN randomised trials Lancet Oncol. 13 July (7) 2012 724 733
43. M. Lamuraglia, B. Escudier, L. Chami, B. Schwartz, J. Leclere, and A. Roche To predict progression-free survival and overall survival in metastatic renal cancer treated with sorafenib: pilot study using dynamic contrast-enhanced doppler ultrasound Eur. J. Cancer 42 October (15) 2006 2472 2479
44. N. Lassau, S. Koscielny, L. Albiges, L. Chami, B. Benatsou, and M. Chebil Metastatic renal cell carcinoma treated with sunitinib: early evaluation of treatment response using dynamic contrast-enhanced ultrasonography Clin. Cancer Res. 16 February (4) 2010 1216 1225
45. M.R. Mancuso, R. Davis, S.M. Norberg, S. O'Brien, B. Sennino, and T. Nakahara Rapid vascular regrowth in tumors after reversal of VEGF inhibition J. Clin. Investig. 116 October (10) 2006 2610 2621
46. R. Minamimoto, N. Nakaigawa, U. Tateishi, A. Suzuki, K. Shizukuishi, and T. Kishida Evaluation of response to multikinase inhibitor in metastatic renal cell carcinoma by FDG PET/contrast-enhanced CT Clin. Nucl. Med. 35 December (12) 2010 918 923
47. R.J. Motzer, T.E. Hutson, P. Tomczak, M.D. Michaelson, R.M. Bukowski, and O. Rixe Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N. Engl. J. Med. 356 January (2) 2007 115 124
48. C. Muriel Lopez, E. Esteban, A. Astudillo, P. Pardo, J.P. Berros, and M. Izquierdo Predictive factors for response to treatment in patients with advanced renal cell carcinoma Investig. New Drugs 30 December (6) 2012 2443 2449
49. M.L. Nickerson, E. Jaeger, Y. Shi, J.A. Durocher, S. Mahurkar, and D. Zaridze Improved identification of von hippel-lindau gene alterations in clear cell renal tumors Clin. Cancer Res. 14 August (15) 2008 4726 4734
50. A.P. Noon, R. Polanski, A.Y. El-Fert, H. Kalirai, H. Shawki, and F. Campbell Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy BJU Int. 109 April (8) 2012 1250 1257
51. M. Nozawa, Y. Yamamoto, T. Minami, N. Shimizu, Y. Hatanaka, and H. Tsuji Sorafenib rechallenge in patients with metastatic renal cell carcinoma BJU Int. 110 September (6 Pt B) 2012 E228 E234
52. M. Paez-Ribes, E. Allen, J. Hudock, T. Takeda, H. Okuyama, and F. Vinals Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell. 15 March (3) 2009 220 231
53. C. Pena, C. Lathia, M. Shan, B. Escudier, and R.M. Bukowski Biomarkers predicting outcome in patients with advanced renal cell carcinoma: results from sorafenib phase III treatment approaches in renal cancer global evaluation trial Clin. Cancer Res. 16 October (19) 2010 4853 4863
54. J.L. Perez-Gracia, C. Prior, F. Guillen-Grima, V. Segura, A. Gonzalez, and A. Panizo Identification of TNF-alpha and MMP-9 as potential baseline predictive serum markers of sunitinib activity in patients with renal cell carcinoma using a human cytokine array Br. J. Cancer 101 December (11) 2009 1876 1883
55. C. Porta, C. Paglino, M. De Amici, S. Quaglini, L. Sacchi, and I. Imarisio Predictive value of baseline serum vascular endothelial growth factor and neutrophil gelatinase-associated lipocalin in advanced kidney cancer patients receiving sunitinib Kidney Int. 77 May (9) 2010 809 815
56. A. Ravaud, and M. Schmidinger Clinical biomarkers of response in advanced renal cell carcinoma Ann. Oncol. 24 December (12) 2013 2935 2942 10.1093/annonc/mdt288
57. B.I. Rini, M.D. Michaelson, J.E. Rosenberg, R.M. Bukowski, J.A. Sosman, and W.M. Stadler Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma J. Clin. Oncol. 26 August (22) 2008 3743 3748
58. B.I. Rini, S. Halabi, J.E. Rosenberg, W.M. Stadler, D.A. Vaena, and L. Archer Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 J. Clin. Oncol. 28 May (13) 2010 2137 2143
59. B.I. Rini, B. Escudier, P. Tomczak, A. Kaprin, C. Szczylik, and T.E. Hutson Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 December (9807) 2011 1931 1939
60. B.I. Rini, D.P. Cohen, D.R. Lu, I. Chen, S. Hariharan, and M.E. Gore Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib J. Natl. Cancer Inst. 103 May (9) 2011 763 773
61. B.I. Rini, M. Garrett, B. Poland, J.P. Dutcher, O. Rixe, and G. Wilding Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis J. Clin. Pharmacol. 53 May (5) 2013 491 504
62. P.C. Rodriguez, M.S. Ernstoff, C. Hernandez, M. Atkins, J. Zabaleta, and R. Sierra Arginase I-producing myeloid-derived suppressor cells in renal cell carcinoma are a subpopulation of activated granulocytes Cancer Res. 69 February (4) 2009 1553 1560
63. E. Rossi, M. Fassan, M. Aieta, F. Zilio, R. Celadin, and M. Borin Dynamic changes of live/apoptotic circulating tumour cells as predictive marker of response to sunitinib in metastatic renal cancer Br. J. Cancer 107 October (8) 2012 1286 1294
64. K. Sharpe, G.D. Stewart, A. Mackay, C. Van Neste, C. Rofe, and D. Berney The effect of VEGF-targeted therapy on biomarker expression in sequential tissue from patients with metastatic clear cell renal cancer Clin. Cancer Res. 19 December (24) 2013 6924 6934 10.1158/1078-0432.CCR-13-1631
65. A.D. Smith, M.L. Lieber, and S.N. Shah Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT AJR Am. J. Roentgenol. 194 January (1) 2010 157 165
66. C.N. Sternberg, I.D. Davis, J. Mardiak, C. Szczylik, E. Lee, and J. Wagstaff Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J. Clin. Oncol. 28 February (6) 2010 1061 1068
67. G. Tanigawa, A. Kawashima, S. Yamaguchi, K. Nishimura, S. Miyoshi, and J. Kajikawa Clinical outcome and prognostic factors of sorafenib in japanese patients with advanced renal cell carcinoma in general clinical practice Jpn. J. Clin. Oncol. 41 November (11) 2011 1265 1270
68. T. Terakawa, H. Miyake, Y. Kusuda, and M. Fujisawa Expression level of vascular endothelial growth factor receptor-2 in radical nephrectomy specimens as a prognostic predictor in patients with metastatic renal cell carcinoma treated with sunitinib Urol. Oncol. 31 May (4) 2013 493 498
69. Y. Tomita, H. Uemura, H. Fujimoto, H.O. Kanayama, N. Shinohara, and H. Nakazawa Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in japanese patients with cytokine-refractory metastatic renal cell carcinoma Eur. J. Cancer 47 November (17) 2011 2592 2602
70. H.T. Tran, Y. Liu, A.J. Zurita, Y. Lin, K.L. Baker-Neblett, and A.M. Martin Prognostic or predictive plasma cytokines and angiogenic factors for patients treated with pazopanib for metastatic renal-cell cancer: a retrospective analysis of phase 2 and phase 3 trials Lancet Oncol. 13 August (8) 2012 827 837
71. D. Tsavachidou-Fenner, N. Tannir, P. Tamboli, W. Liu, D. Petillo, and B. Teh Gene and protein expression markers of response to combined antiangiogenic and epidermal growth factor targeted therapy in renal cell carcinoma Ann. Oncol. 21 August (8) 2010 1599 1606
72. D. Ueno, M. Yao, U. Tateishi, R. Minamimoto, K. Makiyama, and N. Hayashi Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course BMC Cancer 12 May 2012 162 2407-12-162
73. H. van Cruijsen, A.A. van der Veldt, L. Vroling, D. Oosterhoff, H.J. Broxterman, and R.J. Scheper Sunitinib-induced myeloid lineage redistribution in renal cell cancer patients: CD1c+ dendritic cell frequency predicts progression-free survival Clin. Cancer Res. 14 September (18) 2008 5884 5892
74. A.A. van der Veldt, E. Boven, H.H. Helgason, M. van Wouwe, J. Berkhof, and G. de Gast Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer Br. J. Cancer 99 July (2) 2008 259 265
75. A.A. van der Veldt, M.R. Meijerink, A.J. van den Eertwegh, J.B. Haanen, and E. Boven Choi response criteria for early prediction of clinical outcome in patients with metastatic renal cell cancer treated with sunitinib Br. J. Cancer 102 March (5) 2010 803 809
76. A.A. van der Veldt, K. Eechoute, H. Gelderblom, J. Gietema, H.J. Guchelaar, and N.P. van Erp Genetic polymorphisms associated with a prolonged progression-free survival in patients with metastatic renal cell cancer treated with sunitinib Clin. Cancer Res. 17 February (3) 2011 620 629
77. A.A. van der Veldt, L. Vroling, R.R. de Haas, P. Koolwijk, A.J. van den Eertwegh, and J.B. Haanen Sunitinib-induced changes in circulating endothelial cell-related proteins in patients with metastatic renal cell cancer Int. J. Cancer 131 August (4) 2012 E484 E493
78. N.P. van Erp, K. Eechoute, A.A. van der Veldt, J.B. Haanen, A.K. Reyners, and R.H. Mathijssen Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity J. Clin. Oncol. 27 September (26) 2009 4406 4412
79. S. Vanharanta, W. Shu, F. Brenet, A.A. Hakimi, A. Heguy, and A. Viale Epigenetic expansion of VHL-HIF signal output drives multiorgan metastasis in renal cancer Nat. Med. 19 January (1) 2013 50 56
80. N.S. Vasudev, V. Goh, J.K. Juttla, V.L. Thompson, J.M. Larkin, and M. Gore Changes in tumour vessel density upon treatment with anti-angiogenic agents: relationship with response and resistance to therapy Br. J. Cancer 109 September (5) 2013 1230 1242
81. H.M. Verheul, K. Hoekman, S. Luykx-de Bakker, C.A. Eekman, C.C. Folman, and H.J. Broxterman Platelet: transporter of vascular endothelial growth factor Clin. Cancer Res. 3 December (12 Pt 1) 1997 2187 2190
82. J.S. Vermaat, F.L. Gerritse, A.A. van der Veldt, W.M. Roessingh, T.M. Niers, and S.F. Oosting Validation of serum amyloid alpha as an independent biomarker for progression-free and overall survival in metastatic renal cell cancer patients Eur. Urol. 62 October (4) 2012 685 695
83. L. Vroling, A.A. van der Veldt, R.R. de Haas, J.B. Haanen, G.J. Schuurhuis, and D.J. Kuik Increased numbers of small circulating endothelial cells in renal cell cancer patients treated with sunitinib Angiogenesis 12 1 2009 69 79
84. H.M. Westgeest, N.P. van Erp, R.J. Honeywell, R. Hoekstra, G.J. Peters, and H.M. Verheul Successful treatment of renal cell carcinoma with sorafenib after effective but hepatotoxic sunitinib exposure J. Clin. Oncol. 31 February (6) 2013 e83 e86
85. R. Williams, J.M. Hudson, B.A. Lloyd, A.R. Sureshkumar, G. Lueck, and L. Milot Dynamic microbubble contrast-enhanced US to measure tumor response to targeted therapy: a proposed clinical protocol with results from renal cell carcinoma patients receiving antiangiogenic therapy Radiology 260 August (2) 2011 581 590
86. C.F. Xu, N.X. Bing, H.A. Ball, D. Rajagopalan, C.N. Sternberg, and T.E. Hutson Pazopanib efficacy in renal cell carcinoma: evidence for predictive genetic markers in angiogenesis-related and exposure-related genes J. Clin. Oncol. 29 June (18) 2011 2557 2564
87. L. Yang, L.M. DeBusk, K. Fukuda, B. Fingleton, B. Green-Jarvis, and Y. Shyr Expansion of myeloid immune suppressor Gr+CD11b+ cells in tumor-bearing host directly promotes tumor angiogenesis Cancer Cell 6 October (4) 2004 409 421
88. D. You, I.G. Jeong, J.H. Ahn, D.H. Lee, J.L. Lee, and J.H. Hong The value of cytoreductive nephrectomy for metastatic renal cell carcinoma in the era of targeted therapy J. Urol. 185 January (1) 2011 54 59
89. J.L. Yu, J.W. Rak, B.L. Coomber, D.J. Hicklin, and R.S. Kerbel Effect of p53 status on tumor response to antiangiogenic therapy Science 295 February (5559) 2002 1526 1528
90. T. Yuasa, S. Urakami, S. Yamamoto, J. Yonese, K. Nakano, and M. Kodaira Tumor size is a potential predictor of response to tyrosine kinase inhibitors in renal cell cancer Urology 77 April (4) 2011 831 835
91. I.N. Zama, T.E. Hutson, P. Elson, J.M. Cleary, T.K. Choueiri, and D.Y. Heng Sunitinib rechallenge in metastatic renal cell carcinoma patients Cancer 116 December (23) 2010 5400 5406
92. A.J. Zurita, E. Jonasch, X. Wang, M. Khajavi, S. Yan, and D.Z. Du A cytokine and angiogenic factor (CAF) analysis in plasma for selection of sorafenib therapy in patients with metastatic renal cell carcinoma Ann. Oncol. 23 January (1) 2012 46 52